Chronic myelogenous leukaemia.
In the last decade, improvements in both   non-transplant and transplant therapy have   extended the lives of patients with CML,   particularly those in chronic phase. The future will   probably bring a greater understanding of   molecular leukaemogenesis and options for   treating CML. Non-transplant therapies in   development include novel agents and   combination therapy. Transplant strategies seek to   decrease regimen-related toxicity and directly   manipulate the immune system to eradicate   disease. Clinical and laboratory science seems   poised to add novel therapies to the   armamentarium against CML. It is exciting to   contemplate what reviews of CML written 10   years from now will discuss.
Lee
S J
SJ
Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. stephanie_lee@dfci.harvard.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000401:mortality / Q000628:therapy; D015466:Leukemia, Myeloid, Chronic-Phase / Q000235:genetics / Q000401:mortality / Q000628:therapy; D008213:Lymphocyte Activation; D010677:Philadelphia Chromosome; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012008:Recurrence; D012306:Risk; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D007370:Interferon Type I; D011994:Recombinant Proteins